Name of journal: World Journal of Gastroenterology

Manuscript NO: 79540

Title: Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 02445854

Position: Editorial Board

Academic degree: MD

Professional title: Doctor, Research Assistant Professor

Reviewer’s Country/Territory: Italy

Author’s Country/Territory: Poland

Manuscript submission date: 2022-08-26

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-08-27 10:06

Reviewer performed review: 2022-08-27 15:21

Review time: 5 Hours

Scientific quality

[ ] Grade A: Excellent  [ Y] Grade B: Very good  [ ] Grade C: Good
[ ] Grade D: Fair  [ ] Grade E: Do not publish

Language quality

[ ] Grade A: Priority publishing  [ Y] Grade B: Minor language polishing
[ ] Grade C: A great deal of language polishing  [ ] Grade D: Rejection

Conclusion

[ ] Accept (High priority)  [ Y] Accept (General priority)
[ ] Minor revision  [ ] Major revision  [ ] Rejection

Re-review

[ Y] Yes  [ ] No

Peer-reviewer

Peer-Review: [ Y] Anonymous  [ ] Onymous
SPECIFIC COMMENTS TO AUTHORS
This is a well written paper. The results are of interest and the limitations of the study are clearly stated. There are some typos/grammar mistakes that should be corrected.
**Name of journal:** World Journal of Gastroenterology  
**Manuscript NO:** 79540  
**Title:** Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients  
**Provenance and peer review:** Invited manuscript; Externally peer reviewed  
**Peer-review model:** Single blind  
**Reviewer’s code:** 02528485  
**Position:** Peer Reviewer  
**Academic degree:** PhD  
**Professional title:** Professor  
**Reviewer’s Country/Territory:** Taiwan  
**Author’s Country/Territory:** Poland  
**Manuscript submission date:** 2022-08-26  
**Reviewer chosen by:** AI Technique  
**Reviewer accepted review:** 2022-08-28 03:01  
**Reviewer performed review:** 2022-09-04 08:50  
**Review time:** 7 Days and 5 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[Y] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[Y] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[Y] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: [Y] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
In this study, the authors have aimed to identify the most effective interferon-free therapy for GT1b-infected patients and to determine negative predictors of virological response. They have found that the effectiveness of all regimens exceeded 90%, and the highest SVR of 98.9% was achieved in the group of patients treated with a combination of glecaprevir/pibrentasvir. Moreover, Negative predictors for SVR were male sex, HIV-coinfection, decompensated cirrhosis at baseline, HCC history and thrombocytopenia. Several suggestions: 1. In title, please consider [HCV GT1b-infected patients] instead of [HCV patients]. 2. It is better to have a reference after the paragraph of [Antiviral treatment], section of [MATERIALS AND METHODS]. 3. It is better to have a reference after the paragraph of [Treatment effectiveness], section of [MATERIALS AND METHODS]. 4. In the paragraph of [Treatment effectiveness], section of [MATERIALS AND METHODS], it is better to use [reverse transcriptase-polymerase chain reaction (RT-PCR)] instead of [polymerase chain reaction (PCR)].
Name of journal: World Journal of Gastroenterology

Manuscript NO: 79540

Title: Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03664188

Position: Editorial Board

Academic degree: MD

Professional title: Professor

Reviewer’s Country/Territory: Egypt

Author’s Country/Territory: Poland

Manuscript submission date: 2022-08-26

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-08-30 08:18

Reviewer performed review: 2022-09-11 23:24

Review time: 12 Days and 15 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: Anonymous</td>
<td>Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

It is a retrospective multicenter national study on the effect of DAA regimen on HCV genotype 1b carried out on 11385. 1-The running title “DAA therapy in HCV GT1b-infected patients” is not a part of the original title 2- Long background in the abstract. 3- Language needs great correction 4- There is no need to present data for SVR for ITT for patients not followed up. Just present in table4 and figure 1 the results of the 10903 patients SVR at end of therapy and after followed up for 12 weeks post treatment (PP), to avoid confusion in interpreting the data. 5- The current study assess the effectiveness of DAA regimen and not the efficacy, as it is a real world study. 6- other comments are found in the manuscript.
RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 79540

Title: Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03664188

Position: Editorial Board

Academic degree: MD

Professional title: Professor

Reviewer’s Country/Territory: Egypt

Author’s Country/Territory: Poland

Manuscript submission date: 2022-08-26

Reviewer chosen by: Jing-Jie Wang

Reviewer accepted review: 2022-10-10 13:23

Reviewer performed review: 2022-10-12 07:22

Review time: 1 Day and 17 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Peer-reviewer statements</td>
<td>Peer-Review: Anonymous</td>
<td>Onymous</td>
<td>Conflicts-of-Interest: Yes</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

[ ] Yes [ ] No
SPECIFIC COMMENTS TO AUTHORS
Too long abstract 457 words Language of the whole manuscript still needs correction.
The title of tables and figure needs reformulations. Some tables need to be landscape and not portrait Other comments are presented in the manuscript. Carful reading and revision are still needed.